Linking the Provider Recommendation to Adolescent HPV Vaccine Uptake

PAR-19-360 (R01)External Web Site Policy; PAR-19-359 (R03)External Web Site Policy; PAR-19-358 (R21)External Web Site Policy

Thursday November 21, 2019
1:00 PM-2:00 PM EST

View WebinarExternal Web Site Policy

Presentation (PDF, 339 KB)

FAQs (PDF, 116 KB)

The National Cancer Institute has re-issued the Funding Opportunity Announcement (FOA) Linking the Provider Recommendation to Adolescent HPV Vaccine Uptake (Clinical Trial Optional) (PAR-19-360External Web Site Policy [R01]; PAR-19-359External Web Site Policy [R03] and PAR-19-358External Web Site Policy [R21]). This FOA encourages research on how the health care delivery system enhances or inhibits the effectiveness of a provider's recommendation of the adolescent human papillomavirus (HPV) vaccine. Characteristics of the provider, parent/patient, and clinical setting can all affect whether a provider makes a recommendation, and whether that recommendation results in uptake of the HPV vaccine. This research requires expertise in cancer prevention, adult and childhood behavior, immunization promotion, and health care delivery.


Dr. Sarah Kobrin
Chief, Health Systems and Interventions Research Branch
Healthcare Delivery Research Program
Division of Cancer Control and Population Sciences

Intended Audience

Extramural investigators at junior, mid-, and senior levels.

Last Updated: 29 Nov, 2021